BPC-157 — 8 things I got wrong before I got it right
BPC-157 — 8 things I got wrong before I got it right. It is the sort of thing everyone half-believes and nobody writes down.
Every claim I could trace in this board went back to about four papers. That was a sobering afternoon.
Bought small, tested identity first, and only then thought about anything else. That order felt right.
Why identity, not purity, is the test to buy here.
This is a short peptide with a published sequence. Synthesis is not difficult, which means the market is wide and the analytical question shifts. A high area-percent figure tells you the sample is homogeneous; it does not tell you the homogeneous material is the sequence you ordered.
Mass spectrometry, with the theoretical mass alongside the measured one, converts a purity claim into an identity claim. It costs a little more and it answers the question that actually matters. Ask for it, and ask suppliers whether they can provide it before you order — the answers are informative in themselves.
Research-use-only material is not approved for human use and nothing here should be read as a recommendation to use it.
best — the order this archive was captured in
Purity by area percent tells you the sample is homogeneous. Mass spectrometry tells you what the homogeneous thing is. For a short peptide, the second question is the one worth paying for.
Short peptides in solution are subject to hydrolysis and, depending on sequence, oxidation. Storage state and time in solution are practical variables that this board almost never discusses.
Small fix — fifteen residues, not seventeen. The sequence is public and easy to check.
Paid for identity confirmation rather than just purity for the first time here. Worth it, and it is not the default on most certificates.
What jurisdiction are you asking about? The answer has changed in several.
What method produced that purity number?
stability in solution is the practical question nobody asks
no clinical trial has established what these threads assert
[removed by moderator]
Yes. Nothing here is approved for human use and that should be the first line of every thread, not the last.
preclinical enthusiasm is not clinical evidence
Not convinced. A high purity figure with no identity confirmation tells you the sample is homogeneous, not that it is what you ordered.
Same. Solution stability is the practical question and almost nobody asks it.
The published literature is overwhelmingly preclinical, largely in rodent models. Translating a rodent result into a human expectation is not a small step, and almost every confident claim here takes it silently.
Citation requested rather than removal. A claim here should say whether its source is preclinical.
identity, quantity, stability — three separate questions
Kept a reconstituted vial too long out of curiosity and learned something about solution stability I would rather have read.
research-use-only means not approved for human use, and here that covers everything
Right, and regulatory status has genuinely moved in several jurisdictions. Answers from three years ago may be wrong now.
the tendon claims are the most repeated and the least evidenced
Went and read the primary rodent papers after arguing about a summary for a week. They are much narrower than the threads suggest.
That is a purity figure, not an identity confirmation. Two different tests and only one answers the question asked.
Regulatory classification differs between jurisdictions and has changed in several of them recently. Any answer to a status question needs a place and a date attached.
pentadecapeptide, fifteen residues, and the sequence is public
This. Mass spectrometry for identity, not just an area percent, because a pure something-else is still something else.
Asked QYB for the theoretical mass alongside the certificate and they sent it without asking why.
Correction: that study was in rodents. Worth stating explicitly since the thread has been reading it as clinical.
That claim traces back to a single preclinical paper that says something considerably narrower.
Sent a vial to Medutest: 97.6% against a claimed 97.5%, with the mass confirming the sequence. Both halves mattered to me.
Agreed — cheap to make is a double-edged fact and it explains a lot about this corner of the market.
- 1identity, quantity, stability — three separate questions7 comments in this branch · started by u/nadia_nascimento
- 2What method produced that purity number?6 comments in this branch · started by u/slow_logbook_ftw